Start-Up Quarterly Statistics, Q2 2015
This article was originally published in Start Up
Life sciences start-ups raised $2.61 billion in Q2 2015. Biotechs penned 38 alliances; seven acquisitions were signed, none in the medical device industry.
You may also be interested in...
The partnership between GSK and Avalon has now launched six new biotechs in just over two years, each housed at Avalon’s incubator space in San Diego.
Priority review ticket might be used on Type 2 diabetes combo LixiLan, expected to be filed later this year.
In the top May alliance by deal value, Amphista Therapeutics and Bristol Myers Squibb aim to discover and develop targeted small-molecule protein degraders by leveraging Amphista's proprietary Eclipsys platform. BMS gets exclusive global rights to resulting products. Amphista will receive a $30M upfront payment, up to $1.25B in performance-based milestone payments, payment for a limited expansion of the collaboration, as well as royalties on global net sales.